US › Healthcare

Cardiff Oncology Inc (CRDF)

US · Healthcare · Biotechnology

$1.30-3.70%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$104,000

Revenue YoY

-14.0%

Net profit

$-9.2M

EPS

$-0.14

EPS estimate

$-0.17

Net margin

-8,876.9%

EPS came in at -0.14 against a street estimate of -0.17 — a beat of 17.6%.

Key statistics

Market cap

$94.1M

Forward P/E

0.0

P/B

3.53

Book value

$0.39

EPS (TTM)

$-0.60

52-week high

$3.31

52-week low

$0.76

50-day MA

$1.01

200-day MA

$1.70

Beta

1.46

Analyst view

Analysts rate Cardiff Oncology Inc a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $5.28.

Shareholding

Insiders

6.20%

Institutions

21.24%

Largest institutional holders

Fund	Stake
BlackRock Inc	5.12%
Vanguard Capital Management, LLC	3.67%
LAURION CAPITAL MANAGEMENT LP	3.40%
Pfizer Inc	3.10%
Geode Capital Management, LLC	2.06%
Franklin Templeton Inc	1.55%
State Street Corp	1.53%
Blair William & Co	1.17%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cardiff Oncology Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.